^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pumitamig (BNT327)

    i
    Other names: BNT327, BMS986545, PM8002, PM 8002, PM-8002, BNT 327, BNT-327, BMS-986545
    Company:
    BMS, BioNTech
    Drug class:
    PD-L1 inhibitor, VEGF-A inhibitor
    Related drugs:
    8d
    BNT327-06: Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (clinicaltrials.gov)
    P2/3, N=1260, Recruiting, BioNTech SE | Trial completion date: Dec 2030 --> Mar 2030 | Trial primary completion date: Dec 2029 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • pumitamig (BNT327)
    10d
    A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=105, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    gemcitabine • albumin-bound paclitaxel • irinotecan • pumitamig (BNT327)
    26d
    CA244-0001: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=416, Recruiting, Bristol-Myers Squibb | N=238 --> 416 | Trial completion date: Aug 2028 --> Feb 2031 | Trial primary completion date: Dec 2026 --> Feb 2031
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tagrisso (osimertinib) • pumitamig (BNT327) • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    28d
    A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, BioNTech SE
    New P2 trial
    |
    Avastin (bevacizumab) • temozolomide • pumitamig (BNT327)
    30d
    A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (clinicaltrials.gov)
    P1/2, N=129, Not yet recruiting, Bristol-Myers Squibb
    New P1/2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • pumitamig (BNT327)
    30d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) (clinicaltrials.gov)
    P1/2, N=264, Not yet recruiting, Bristol-Myers Squibb
    New P1/2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • pumitamig (BNT327)
    1m
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=990, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • pumitamig (BNT327)
    2ms
    A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=105, Not yet recruiting, BioNTech SE
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • irinotecan • pumitamig (BNT327)
    2ms
    BNT327-03: Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer (clinicaltrials.gov)
    P3, N=621, Recruiting, BioNTech SE | Active, not recruiting --> Recruiting | N=439 --> 621 | Trial completion date: Sep 2028 --> Mar 2029 | Trial primary completion date: Apr 2028 --> Dec 2028
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV • pumitamig (BNT327)
    2ms
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=558, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    3ms
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=990, Not yet recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • pumitamig (BNT327)
    3ms
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=690, Not yet recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)